INTRODUCTION
Since the third International Workshop on Chromosomes in Leukemia in 1980, cytogenetic abnormalities have been established to be very important for the prognosis of ALL [1] . Abnormal karyotypes have been reported in up to 80% of children and 70% of adults with ALL [2] . Abnormalities in the short arm of chromosome 12 are common in childhood ALL and t(12;21)(p13;q22) are well-known chromosomal abnormalities. However, t(12;17) (p13;q21) is a rare cytogenetic abnormality in patients with ALL. To the best of our knowledge, approximately 20 cases of this abnormality have been reported in the literature [1, [3] [4] [5] [6] [7] [8] [9] . In this study, we report presumably the first case of this abnormality in Korea, thereby facilitating the delineation of a distinct subtype of ALL.
CASE REPORT
A 57-yr-old woman was admitted to our hospital for the treatment of pancytopenia. On admission, her medical history and physical examination findings were unremarkable. Peripheral blood examination showed the following findings: Hb level, 8.8 g/dL; leukocyte count, 3,120/µL; and platelet count, 37,000/µL with 2% neutrophils, 39% lymphocytes, 55% blasts, and 5 nucleated red cells per hundred of white blood cells (Fig. 1A) . On the basis of these findings, we suspected acute leukemia 
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Patients with ALL rarely present with t(12;17)(p13;q21) as the primary clonal abnormality; this abnormality is associated with the expression of myeloid antigens. In this study, we have reported presumably the first case of this chromosomal abnormality in Korea, thereby facilitating the delineation of a distinct subtype of ALL. A 57-yr-old woman was referred to our hospital because of pancytopenia. Peripheral blood examination showed 55% blasts. The bone marrow was markedly hypercellular, and about 82.4% of all nucleated cells were blasts. The results of immunophenotyping and cytochemical staining suggested early precursor B-ALL. Cytogenetic analysis of the bone marrow cells showed a complex karyotype, including a reciprocal translocation between the short arm of chromosome 12 and the long arm of chromosome 17, t(12;17)(p13;q21). Data from array comparative genomic hybridization were almost consistent with the cytogenetic findings. (Fig. 2) . 
DISCUSSION
Translocation (12;17) has been reported mainly in children and young adults with ALL and AML [1, [3] [4] [5] [6] [7] [8] [9] . The assignment of translocation breakpoint has been reported to be slightly different among different studies, but some or all of those cases are likely to represent the same translocation because breakpoint assignment is quite subjective [5] .
Krance et al. [5] reported 5 patients with early pre-B ALL and t(12;17)(p13;q21). However, 2 patients expressed the myeloid-associated antigen CD33, and the CD10 antigen was absent or present at low levels in all 5 patients.
Complete remission was achieved in all 5 patients. During subsequent therapy, 2 patients relapsed and 3 remained in continuous remission for more than 20 months.
Another study reported that 2 cases of t(12;17) in ALL had a precursor-B immunophenotype and were CD33 positive and CD10 negative. These patients also achieved complete remission and remained in that condition [8] .
Our findings were also similar to those reported above:
precursor B-ALL, positivity for CD33, negativity for CD 10, and favorable prognosis.
Some reports suggest that the expression of myeloid antigen on ALL leukemic cells has an adverse prognostic influence. However, other researchers have argued that the coexpression of myeloid-associated antigens in the cases of B-cell progenitor ALL has no prognostic significance in childhood ALL [5] . Lack of CD10 expression has been associated with adverse biologic and clinical features [8] . Further, low levels of CD10 expression have been reported to be associated with a higher rate of induction failure, but they have no other prognostic significance in B-cell lineage ALL [5] . The t(12;17) abnormality has been reported to be associated with a poor prognosis [4, 6] ;
however, a favorable prognosis was observed in some cases, including ours. Currently, not many cases have been reported, and therefore, a robust relationship between the prognosis and the expressions of CD33 and CD10
cannot be determined.
The characteristic feature of our case was that it had t(12;17) as well as an additional der (12) In summary, t(12;17)(p13;q21) is a rare chromosomal abnormality of ALL and is associated with the expression of myeloid antigens. In this study, we report a case of ALL with the chromosomal abnormality t(12;17) (p13;q21), which was identified by conventional cytogenetics and array CGH. Our case indicates that cytogenetic and molecular studies are important for the accurate diagnosis of this unusual clonal abnormality and further analyses of such cases are required to accurately define this rare disease entity.
